ANGIODYNAMICS INC
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Sale $2,000.00 |
Oct 24, 2025 | Oct 20, 2025 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 25, 2025 | Jun 27, 2025 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Sale $1,001 - $15,000 |
Jul 25, 2025 | Jul 16, 2025 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Sale $1,001 - $15,000 |
Dec 25, 2016 | Nov 8, 2016 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 6, 2016 | Apr 27, 2016 | Filing ↗ |
Debbie Wasserman SchultzHouse · D · FL |
ANGOANGIODYNAMICS INC · Stock |
Purchase $1,001 - $15,000 |
Jul 6, 2016 | Apr 27, 2016 | Filing ↗ |
Whale Activity
- Increased63
- New28
- Held29
- Decreased45
- Closed20
- No prior filing7
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 4.0M | $62.3M | increased |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 2.6M | $40.1M | decreased |
| ROYCE & ASSOCIATES LP | 1.9M | $29.6M | decreased |
| Broadfin Holdings LLC | 1.8M | $27.1M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7M | $26.3M | increased |
| ARMISTICE CAPITAL, LLC | 1.5M | $23.6M | decreased |
| WEBER CAPITAL MANAGEMENT LLC /ADV | 1.3M | $20.8M | decreased |
| TWO SIGMA INVESTMENTS, LP | 1.3M | $19.6M | increased |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.0M | $15.9M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.0M | $15.6M | decreased |
| STATE STREET CORP | 990.2K | $15.2M | increased |
| Point72 Asset Management, L.P. | 965.0K | $14.8M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Trowbridge Stephen AEVP and CFO | Sale | −23.6K | $12.27 | $290K | Oct 29, 2026 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Sale | −1,720 | $12.17 | $21K | Oct 28, 2026 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Sale | −23.4K | $14.72 | $344K | Jul 30, 2026 | Form 4 ↗ |
| Piccinini LauraSVP International | Tax withholding | −4,506 | $13.82 | $62K | Jul 22, 2026 | Form 4 ↗ |
| Piccinini LauraSVP International | Option exercise | +8,047 | $0.00 | $0 | Jul 22, 2026 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Tax withholding | −1,671 | $13.82 | $23K | Jul 22, 2026 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Option exercise | +5,694 | $0.00 | $0 | Jul 22, 2026 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Tax withholding | −8,319 | $13.82 | $115K | Jul 22, 2026 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Option exercise | +16.3K | $0.00 | $0 | Jul 22, 2026 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −26.7K | $13.82 | $369K | Jul 22, 2026 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Option exercise | +52.4K | $0.00 | $0 | Jul 22, 2026 | Form 4 ↗ |
| Campbell Chad ThomasSVP/GM, Vascular Access | Tax withholding | −2,330 | $13.82 | $32K | Jul 22, 2026 | Form 4 ↗ |
| Campbell Chad ThomasSVP/GM, Vascular Access | Option exercise | +6,466 | $0.00 | $0 | Jul 22, 2026 | Form 4 ↗ |
| Trowbridge Stephen AEVP and CFO | Tax withholding | −717 | $13.71 | $10K | Jul 20, 2026 | Form 4 ↗ |
| Piccinini LauraSVP International | Tax withholding | −616 | $13.71 | $8K | Jul 20, 2026 | Form 4 ↗ |
| Nighan Warren JRSVP Quality and Regulatory | Tax withholding | −251 | $13.71 | $3K | Jul 20, 2026 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −4,223 | $13.71 | $58K | Jul 20, 2026 | Form 4 ↗ |
| Campbell Chad ThomasSVP/GM, Vascular Access | Tax withholding | −359 | $13.71 | $5K | Jul 20, 2026 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −487 | $13.51 | $7K | Jul 19, 2026 | Form 4 ↗ |
| Clemmer James CPresident and CEO · Director | Tax withholding | −11.8K | $13.51 | $159K | Jul 19, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $15.3M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 973.1K | $12.7M | 0.02% | Jun 30, 2026 |
| Royce Small-Cap Opportunity Fund ROYCE FUND | 707.4K | $9.2M | 0.65% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account College Retirement Equities Fund | 626.5K | $8.2M | 0.01% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 484.8K | $6.3M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 406.7K | $6.0M | 0.02% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund TIAA-CREF Funds | 382.5K | $5.7M | 0.14% | Jul 31, 2026 |
| First Eagle Small Cap Opportunity Fund First Eagle Funds | 310.7K | $4.6M | 0.16% | Jul 31, 2026 |
| ROYCE MICRO-CAP TRUST, INC. | 283.9K | $3.7M | 0.41% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund BlackRock Funds | 228.7K | $3.7M | 0.07% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list ANGO's shares (CUSIP 03475V101), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Steven A. CohenSCHEDULE 13G/A · passive (13G) · 965.0K shares2.3%
Nov 16, 2026 · ↗ - Point72 Capital Advisors, Inc.SCHEDULE 13G/A · passive (13G) · 965.0K shares2.3%
Nov 16, 2026 · ↗ - Point72 Asset Management, L.P.SCHEDULE 13G/A · passive (13G) · 965.0K shares2.3%
Nov 16, 2026 · ↗ - Steven A. CohenSCHEDULE 13G/A · passive (13G) · 3.2M shares7.7%
May 15, 2026 · ↗ - Point72 Capital Advisors, Inc.SCHEDULE 13G/A · passive (13G) · 3.2M shares7.7%
May 15, 2026 · ↗ - Point72 Asset Management, L.P.SCHEDULE 13G/A · passive (13G) · 3.2M shares7.7%
May 15, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming ANGIODYNAMICS INC as the client.
Government Contracts
No federal contract awards found for ANGIODYNAMICS INC.
U.S. Patents
No USPTO patent applications found for ANGIODYNAMICS INC.
Annual Financials
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $320.2M | $292.5M | $303.9M | $338.8M | $316.2M |
| Operating income | -$39.9M | -$40.0M | -$192.4M | -$51.2M | -$28.5M |
| Net income | -$36.7M | -$34.0M | -$184.3M | -$52.4M | -$26.5M |
| Diluted EPS | -$0.88 | -$0.83 | -$4.59 | -$1.33 | -$0.68 |
| Operating cash flow | $3.1M | -$10.1M | -$28.2M | $78K | -$7.2M |
| Cash and equivalents | $53.9M | $55.9M | $76.1M | $44.6M | $28.8M |
| Total assets | $267.2M | $280.1M | $317.7M | $532.6M | $552.8M |
| Total liabilities | $96.3M | $97.2M | $112.1M | $154.3M | $128.3M |
| Shareholders' equity | $170.8M | $183.0M | $205.6M | $378.3M | $424.5M |
As ANGIODYNAMICS INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Jul 14, 2026 ↗
Stock Splits
No stock splits in ANGO's price history.
Material Events (8-K)
- 8-K · Items 5.02, 5.07, 9.01Officer / director change · Shareholder voteNov 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureOct 8, 2026
EDGAR ↗ - 8-K · Items 1.01, 5.02, 9.01Material agreement · Officer / director changeOct 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureJul 14, 2026
EDGAR ↗
About ANGIODYNAMICS INC
. OVERVIEW AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance. HISTORY AngioDynamics was founded in Queensbury, N.Y., U.S., in 1988 and began manufacturing and shipping product in the early 1990s. The Company is headquartered in Latham, N.Y., with manufacturing primarily out of the Queensbury…

